Quantcast

Latest Parathyroid gland Stories

2008-09-16 12:00:50

NPS Pharmaceuticals has reported positive interim data from an investigator-initiated Phase II proof-of-concept study of NPSP558, the proprietary recombinant full-length human parathyroid hormone for the treatment of hypoparathyroidism. The interim data demonstrated that treatment with the proprietary recombinant full-length human parathyroid hormone (PTH 1-84) had a beneficial effect on abnormal bone skeletal properties in patients with hypoparathyroidism, a rare condition typified by...

2008-09-15 09:00:11

At the 30th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR), positive interim data were presented from an investigator-initiated Phase 2 proof-of-concept study of NPSP558, the proprietary recombinant full-length human parathyroid hormone (PTH 1-84) under development by NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) for the treatment of hypoparathyroidism. In one plenary poster and two oral presentations, the interim data demonstrated that treatment with PTH 1-84 had a...

2008-08-30 09:00:20

By DeLellis, Ronald A Mazzaglia, Peter; Mangray, Shamlal Context.-Primary hyperparathyroidism (P-HPT) is one of the most common of all endocrine disorders. Eighty percent to 85% of cases are due to parathyroid adenomas while hyperplasia and carcinoma account for 10% to 15% and less than 1%, of cases, respectively. The past decade has witnessed remarkable advances in the understanding of the molecular basis of parathyroid hyperplasia and neoplasia. Additionally, imaging studies and the...

2008-07-30 09:00:23

MARKHAM, ON, and OSAKA, Japan, July 30 /PRNewswire/ -- Cytochroma and Mitsubishi Tanabe Pharma Corporation ("MTPC") today announced that the companies have signed a license agreement under which Cytochroma granted MTPC an exclusive license in the U.S. and Asia, including Japan, to develop and commercialize CTA018, Cytochroma's novel vitamin D analog. CTA018 is entering Phase II development in Canada for the treatment of secondary hyperparathyroidism ("SHPT") in patients with chronic kidney...

2008-06-30 09:02:02

CEDAR KNOLLS, N.J., June 30 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. announced today that Novartis Pharma AG has launched a Phase I study in postmenopausal women to determine the safety and tolerability of oral PTH134, a combination of human PTH-1-34 and the absorption enhancer 5-CNAC using Emisphere's proprietary Eligen(R) technology, for the treatment of postmenopausal osteoporosis. The study is designed to assess the bioavailability profile of increasing doses of PTH-1-34...

2008-06-16 18:00:39

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported the receipt of Paragraph IV Certification Notice Letters related to certain drug manufacturers' Abbreviated New Drug Applications (ANDA) submitted to the U.S. Food and Drug Administration (FDA) requesting approval to market and sell generic versions of Sensipar(R) (cinacalcet HCl), a drug licensed to Amgen by NPS. Under NPS's licensing agreement with Amgen, Amgen is responsible for all development and commercial activities involving...

2007-07-01 06:19:07

By Richards, Melanie L Grant, Clive S Parathyroid hormone measurement using a two-site immunochemiluminometric assay has allowed for a rapid and accurate technique that has found its way into the operative armamentarium of some parathyroid surgeons. It can be used to assess the completeness of parathyroid gland resection and allow for a minimally invasive parathyroidectomy. This operative approach has become a popular marketing tool, providing patients with confidence in their surgical...

2005-11-29 14:20:29

Changes in a widely used assay (blood test) for parathyroid hormone (PTH) have made its use with the established guidelines for end stage renal disease clinical management both inappropriate and potentially harmful to patients. This research is published in the journal Seminars in Dialysis. A PTH assay measures levels of parathyroid hormone, produced by the parathyroid gland, which helps diagnose conditions such as hyperparathyroidism or to determine causes of abnormal regulation of calcium...

2005-11-09 13:45:46

NEW YORK (Reuters Health) - For maintaining calcium metabolism, intake of calcium levels above 800 milligrams daily is probably unnecessary provided that vitamin D status is adequate, according to a report in the Journal of the American Medical Association this week. Vitamin D is essential to healthy teeth and bones, and it helps the body absorb and use calcium, but the ideal intake of vitamin D has been unclear, senior author Dr. Gunnar Sigurdsson, from Landspitali-University...

2005-11-09 13:45:00

NEW YORK (Reuters Health) - For maintaining calcium metabolism, intake of calcium levels above 800 milligrams daily is probably unnecessary provided that vitamin D status is adequate, according to a report in the Journal of the American Medical Association this week. Vitamin D is essential to healthy teeth and bones, and it helps the body absorb and use calcium, but the ideal intake of vitamin D has been unclear, senior author Dr. Gunnar Sigurdsson, from Landspitali-University Hospital in...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related